183 related articles for article (PubMed ID: 36747324)
1. Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study.
Yoshihara K; Baba T; Tokunaga H; Nishino K; Sekine M; Takamatsu S; Matsumura N; Yoshida H; Kajiyama H; Shimada M; Kagimura T; Oda K; Sasajima Y; Yaegashi N; Okamoto A; Sugiyama T; Enomoto T
Cancer Sci; 2023 Jun; 114(6):2515-2523. PubMed ID: 36747324
[TBL] [Abstract][Full Text] [Related]
2. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
3. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
4. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
Takamatsu S; Yoshihara K; Baba T; Shimada M; Yoshida H; Kajiyama H; Oda K; Mandai M; Okamoto A; Enomoto T; Matsumura N
Br J Cancer; 2023 Apr; 128(6):1095-1104. PubMed ID: 36593360
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
7. Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Thomas SN; Chen L; Liu Y; Höti N; Zhang H
J Proteome Res; 2017 Oct; 16(10):3704-3710. PubMed ID: 28866885
[TBL] [Abstract][Full Text] [Related]
8. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
9. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
11. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Pothuri B
Ann Oncol; 2013 Nov; 24 Suppl 8():viii22-viii27. PubMed ID: 24131965
[TBL] [Abstract][Full Text] [Related]
12. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
de Jonge MM; Auguste A; van Wijk LM; Schouten PC; Meijers M; Ter Haar NT; Smit VTHBM; Nout RA; Glaire MA; Church DN; Vrieling H; Job B; Boursin Y; de Kroon CD; Rouleau E; Leary A; Vreeswijk MPG; Bosse T
Clin Cancer Res; 2019 Feb; 25(3):1087-1097. PubMed ID: 30413523
[TBL] [Abstract][Full Text] [Related]
13. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
14. Structural Variants at the
Ewing A; Meynert A; Churchman M; Grimes GR; Hollis RL; Herrington CS; Rye T; Bartos C; Croy I; Ferguson M; Lennie M; McGoldrick T; McPhail N; Siddiqui N; Dowson S; Glasspool R; Mackean M; Nussey F; McDade B; Ennis D; McMahon L; Matakidou A; Dougherty B; March R; Barrett JC; McNeish IA; ; Biankin AV; Roxburgh P; Gourley C; Semple CA
Clin Cancer Res; 2021 Jun; 27(11):3201-3214. PubMed ID: 33741650
[TBL] [Abstract][Full Text] [Related]
15. Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Roussel-Simonin C; Blanc-Durand F; Tang R; Vasseur D; Le Formal A; Chardin L; Yaniz E; Gouy S; Maulard A; Scherier S; Sanson C; Lacroix L; Cotteret S; Mauny L; Zaccarini F; Rouleau E; Leary A
Mol Cancer; 2023 Nov; 22(1):178. PubMed ID: 37932736
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
18. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Romey M; Rodepeter F; Hattesohl A; Kaiser K; Teply-Szymanski J; Heitz F; Staebler A; Serra V; Grass A; Marmé F; Timms KM; Harter P; Llop-Guevara A; Kommoss S; Boekhoff J; Denkert C
Mod Pathol; 2024 Apr; 37(4):100445. PubMed ID: 38341130
[TBL] [Abstract][Full Text] [Related]
19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
20. Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling.
Denkert C; Romey M; Swedlund B; Hattesohl A; Teply-Szymanski J; Kommoss S; Kaiser K; Staebler A; du Bois A; Grass A; Knappmeyer C; Heitz F; Solimeno C; Ebel T; Harter P; Marmé F; Jank P; Gaiser T; Neff C; Wagner U; Timms KM; Rodepeter F
J Mol Diagn; 2022 Dec; 24(12):1254-1263. PubMed ID: 36191839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
